Retatrutide

Retatrutide is a triple agonist targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCGR) receptors

It is being studied for the treatment of obesity, type 2 diabetes (T2D), and metabolic dysfunction-associated steatotic liver disease (MASLD), with potential applications for other metabolic conditions like non-alcoholic fatty liver disease (NAFLD), obstructive sleep apnea, and knee osteoarthritis. Unlike dual agonists like tirzepatide or single agonists like semaglutide, Retatrutide’s triple-receptor action aims to enhance weight loss, glycemic control, and metabolic health by synergistically regulating appetite, insulin secretion, glucose metabolism, and energy expenditure. One major benefit of Retatrutide is MUSCLE PRESERVATION. Unlike some weight loss drugs, Retatrutide may preserve lean muscle mass, reducing frailty risk

Mechanism of Action:

GLP-1 Receptor Agonism: Stimulates insulin secretion (glucose-dependent), slows gastric emptying, suppresses appetite, and enhances satiety

GIP Receptor Agonism: Enhances insulin release post-meal, improves insulin sensitivity, and may contribute to weight loss

Glucagon Receptor Agonism: Increases energy expenditure, promotes fat mobilization, and reduces liver fat, while GLP-1/GIP activity prevents hyperglycemia